Dr Preeyaporn Srasuebkul

A15 - Pharmacy And Bank Building
The University of Sydney

Biographical details

Dr Preeyaporn Srasuebkul is a post-doctoral biostatistician with the Pharmacoepidemiology and Pharmaceutical Policy Research Group, University of Sydney. She has expertise in analysing large data sets to explore the use and impact of prescribed medicines. Specifically, she has extensive experience in analysing clinical trial and health administrative data.

Research interests

  • Biostatistics
  • Analyses of linked data
  • Observational databases

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Srasuebkul, P., Dobbins, T., Pearson, S. (2014). Validation of a proxy for estrogen receptor status in breast cancer patients using dispensing data. Asia-Pacific Journal of Clinical Oncology, 10(2), e63-e68. [More Information]
  • Lu, C., Srasuebkul, P., Drew, A., Chen, K., Ward, R., Pearson, S. (2013). Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function? The Breast, 22(4), 482-487. [More Information]
  • Lu, C., Srasuebkul, P., Drew, A., Ward, R., Pearson, S. (2011). Positive spillover effects of prescribing requirements: Increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. Internal Medicine Journal, (Online preview). [More Information]
  • Hansudewechakul, R., Sirisanthana, V., Kurniati, N., Puthanakit, T., Lumbiganon, P., Saphonn, V., Yusoff, N., Kumarasamy, N., Fong, S., Nallusamy, R., et al (2010). Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 55(4), 503-509.
  • Puls, R., Srasuebkul, P., Petoumenos, K., Boesecke, C., Duncombe, C., Belloso, W., Molina, J., Li, L., Avihingsanon, A., Gazzard, B., et al (2010). Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clinical Infectious Diseases, 51(7), 855-864. [More Information]
  • Pujari, S., Srasuebkul, P., Sungkanuparph, S., Lim, P., Kumarasamy, N., Chuah, J., Kumar, R., Chen, Y., Oka, S., Choi, J., et al (2009). Patient characteristics and treatment outcome associated with Protease Inhibitor (PI) use in the Asia-Pacific region. Journal of Antivirals and Antiretrovirals, 1(1), 28-35. [More Information]
  • Srasuebkul, P., Sungkanuparph, S., Lim, P., Law, M. (2009). Reply to DiNubile. Clinical Infectious Diseases, 49, 811-812. [More Information]
  • Srasuebkul, P., Lim, P., Lee, M., Kumarasamy, N., Zhou, J., Sirisanthana, T., Li, P., Kamarulzaman, A., Oka, S., Phanuphak, P., et al (2009). Short Term Clinical Disease Progression in HIV Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database. Clinical Infectious Diseases, 48(7), 940-950. [More Information]
  • Nuesch, R., Ananworanich, J., Srasuebkul, P., Chetchotisakd, P., Prasithsirikul, W., Klinbuayam, W., Mahanontharit, A., Juppimai, T., Ruxrungtham, K., Hirschel, B. (2008). Interruptions of tenofovir/emtricitabine based ART in patients with HIV/HBV co-infection. AIDS, 22(1), 152-154. [More Information]
  • Srasuebkul, P., Calmy, A., Zhou, J., Kumarasamy, N., Law, M., Lim, P. (2007). Impact of drug classes and threatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Databade (TAHOD). AIDS Research and Therapy, 4(18), 1-10. [More Information]
  • Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M., Phanuphak, P., Cooper, D., Law, M. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54.
  • Boyd, M., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., Ubolyam, S., Burger, D., Reiss, P., Stek Jr, M., et al (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232.
  • Boyd, M., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., Wangsuphachart, S., Krisanachinda, A., Lerdlum, S., Lange, J., et al (2006). Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to retonavir-boosted indinavir and efavirenz. The Journal of Infectious Diseases, 194(5), 642-650.
  • Nuesch, R., Srasuebkul, P., Ananworanich, J., Ruxrungtham, K., Phanuphak, P., Duncombe, C. (2006). Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. Journal of Antimicrobial Chemotherapy, 58(3), 637-644. [More Information]
  • Boyd, M., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P., Uchaipichat, V., Stek Jr, M., Lange, J., Phanuphak, P., Cooper, D., Udomuksorn, W., et al (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmocogenet Genomics, 16(5), 321-329. [More Information]
  • Cardiello, P., Hassink, E., Ananworanich, J., Srasuebkul, P., Samor, T., Mahanontharit, A., Ruxrungtham, K., Hirschel, B., Lange, J., Phanuphak, P., et al (2005). A propspective, randomised trial of structured treatment interruption for patients with chronic HIV Type 1 infection. Clinical Infectious Diseases, 40(4), 594-560.
  • Cardiello, P., Srasuebkul, P., Hassink, E., Mahanontharit, A., Samor, T., Ruxrungtham, K., Lange, J., Cooper, D., Phanuphak, P. (2005). The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. HIV Medicine, 6(2), 122-128.
  • Ungsedhapand, C., Srasuebkul, P., Cardiello, P., Ruxrungtham, K., Ratanasuwan, W., Kroon, E., Tongtalung, M., Juengprasert, N., Ubolyam, S., Siangphoe, U., et al (2004). Three-year durability of dual-nucleoside therapy in a Thai population with HIV infection. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 36(2), 693-701. [More Information]
  • Ananworanich, J., Nuesch, R., Teeratakulpisarn, S., Srasuebkul, P., Chuenyam, T., Siangphoe, U., Ungsedhaphand, C., Phanuphak, P., Ruxrungtham, K. (2003). In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 32(5), 570-572.
  • Pothikamjorn, S., Ruxrungtham, K., Thampanitchawong, P., Fuangthong, R., Srasuebkul, P., sangahsapaviriyah, A., Suttithavil, W., Klaewsongkram, J., Parisuthikul, V., Viravan, T., et al (2002). Impact of particulate air pollutants on allergic diseases, allergic skin reactivity and lung function. Asian Pacific Journal of Allergy and Immunology, 20(2), 77-83.
  • Cardiello, P., van Heeswijk, R., Hassink, E., Srasuebkul, P., Mahanontharit, A., Samor, T., Worarien, W., Beijnen, J., Hoetelmans, R., Ruxrungtham, K., et al (2002). Simplifying protease inhibitor therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100mg): HIVNAT 001.3 Study. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 29(5), 464-470.

Conferences

  • Srasuebkul, P., Pearson, S., Harris, C., Ward, R., Dobbins, T. (2010). The impact of oestrogen receptor (ER) status on overall survival of metastatic breast cancer patients receiving trastuzumab in Australia. 16th Annual Japanese Society for Pharmacoepidemiology Meeting and the 5th Annual Asian Conference on Pharmacoepidemiology, Japan: ACPE.
  • Srasuebkul, P. (2005). Parametric models to predict immunological failure in Thai patients receiving Antiretroviral therapy. Australasia society for HIV medicine conference 2005, Hobart: ASHM - Australasian Society for HIV Medicine.
  • Srasuebkul, P. (2001). The Long-term efficacy of saquinavir-soft gelatin capsules plus either Combivir (AZT/3TC) or ddl/d4T in HIV1+ Thai patients pretreated with AZT/ddC: HIV-NAT 001.1 and 001.2. Royal College of Physicians of Thailand Meeting 2001, Thailand: Royal College of Physicians of Thailand.

2014

  • Srasuebkul, P., Dobbins, T., Pearson, S. (2014). Validation of a proxy for estrogen receptor status in breast cancer patients using dispensing data. Asia-Pacific Journal of Clinical Oncology, 10(2), e63-e68. [More Information]

2013

  • Lu, C., Srasuebkul, P., Drew, A., Chen, K., Ward, R., Pearson, S. (2013). Trastuzumab therapy in Australia: Which patients with HER2+ metastatic breast cancer are assessed for cardiac function? The Breast, 22(4), 482-487. [More Information]

2011

  • Lu, C., Srasuebkul, P., Drew, A., Ward, R., Pearson, S. (2011). Positive spillover effects of prescribing requirements: Increased cardiac testing in patients treated with trastuzumab for HER2+ metastatic breast cancer. Internal Medicine Journal, (Online preview). [More Information]

2010

  • Hansudewechakul, R., Sirisanthana, V., Kurniati, N., Puthanakit, T., Lumbiganon, P., Saphonn, V., Yusoff, N., Kumarasamy, N., Fong, S., Nallusamy, R., et al (2010). Antiretroviral therapy outcomes of HIV-infected children in the TREAT Asia pediatric HIV observational database. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 55(4), 503-509.
  • Puls, R., Srasuebkul, P., Petoumenos, K., Boesecke, C., Duncombe, C., Belloso, W., Molina, J., Li, L., Avihingsanon, A., Gazzard, B., et al (2010). Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clinical Infectious Diseases, 51(7), 855-864. [More Information]
  • Srasuebkul, P., Pearson, S., Harris, C., Ward, R., Dobbins, T. (2010). The impact of oestrogen receptor (ER) status on overall survival of metastatic breast cancer patients receiving trastuzumab in Australia. 16th Annual Japanese Society for Pharmacoepidemiology Meeting and the 5th Annual Asian Conference on Pharmacoepidemiology, Japan: ACPE.

2009

  • Pujari, S., Srasuebkul, P., Sungkanuparph, S., Lim, P., Kumarasamy, N., Chuah, J., Kumar, R., Chen, Y., Oka, S., Choi, J., et al (2009). Patient characteristics and treatment outcome associated with Protease Inhibitor (PI) use in the Asia-Pacific region. Journal of Antivirals and Antiretrovirals, 1(1), 28-35. [More Information]
  • Srasuebkul, P., Sungkanuparph, S., Lim, P., Law, M. (2009). Reply to DiNubile. Clinical Infectious Diseases, 49, 811-812. [More Information]
  • Srasuebkul, P., Lim, P., Lee, M., Kumarasamy, N., Zhou, J., Sirisanthana, T., Li, P., Kamarulzaman, A., Oka, S., Phanuphak, P., et al (2009). Short Term Clinical Disease Progression in HIV Infected Patients Receiving Combination Antiretroviral Therapy: Results from the TREAT Asia HIV Observational Database. Clinical Infectious Diseases, 48(7), 940-950. [More Information]

2008

  • Nuesch, R., Ananworanich, J., Srasuebkul, P., Chetchotisakd, P., Prasithsirikul, W., Klinbuayam, W., Mahanontharit, A., Juppimai, T., Ruxrungtham, K., Hirschel, B. (2008). Interruptions of tenofovir/emtricitabine based ART in patients with HIV/HBV co-infection. AIDS, 22(1), 152-154. [More Information]

2007

  • Srasuebkul, P., Calmy, A., Zhou, J., Kumarasamy, N., Law, M., Lim, P. (2007). Impact of drug classes and threatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Databade (TAHOD). AIDS Research and Therapy, 4(18), 1-10. [More Information]
  • Srasuebkul, P., Ungsedhapand, C., Ruxrungtham, K., Boyd, M., Phanuphak, P., Cooper, D., Law, M. (2007). Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment. HIV Medicine, 8(1), 46-54.

2006

  • Boyd, M., Srasuebkul, P., Khongphattanayothin, M., Ruxrungtham, K., Hassink, E., Duncombe, C., Ubolyam, S., Burger, D., Reiss, P., Stek Jr, M., et al (2006). Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antiviral Therapy, 11(2), 223-232.
  • Boyd, M., Carr, A., Ruxrungtham, K., Srasuebkul, P., Bien, D., Law, M., Wangsuphachart, S., Krisanachinda, A., Lerdlum, S., Lange, J., et al (2006). Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to retonavir-boosted indinavir and efavirenz. The Journal of Infectious Diseases, 194(5), 642-650.
  • Nuesch, R., Srasuebkul, P., Ananworanich, J., Ruxrungtham, K., Phanuphak, P., Duncombe, C. (2006). Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. Journal of Antimicrobial Chemotherapy, 58(3), 637-644. [More Information]
  • Boyd, M., Srasuebkul, P., Ruxrungtham, K., Mackenzie, P., Uchaipichat, V., Stek Jr, M., Lange, J., Phanuphak, P., Cooper, D., Udomuksorn, W., et al (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmocogenet Genomics, 16(5), 321-329. [More Information]

2005

  • Cardiello, P., Hassink, E., Ananworanich, J., Srasuebkul, P., Samor, T., Mahanontharit, A., Ruxrungtham, K., Hirschel, B., Lange, J., Phanuphak, P., et al (2005). A propspective, randomised trial of structured treatment interruption for patients with chronic HIV Type 1 infection. Clinical Infectious Diseases, 40(4), 594-560.
  • Srasuebkul, P. (2005). Parametric models to predict immunological failure in Thai patients receiving Antiretroviral therapy. Australasia society for HIV medicine conference 2005, Hobart: ASHM - Australasian Society for HIV Medicine.
  • Cardiello, P., Srasuebkul, P., Hassink, E., Mahanontharit, A., Samor, T., Ruxrungtham, K., Lange, J., Cooper, D., Phanuphak, P. (2005). The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy. HIV Medicine, 6(2), 122-128.

2004

  • Ungsedhapand, C., Srasuebkul, P., Cardiello, P., Ruxrungtham, K., Ratanasuwan, W., Kroon, E., Tongtalung, M., Juengprasert, N., Ubolyam, S., Siangphoe, U., et al (2004). Three-year durability of dual-nucleoside therapy in a Thai population with HIV infection. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 36(2), 693-701. [More Information]

2003

  • Ananworanich, J., Nuesch, R., Teeratakulpisarn, S., Srasuebkul, P., Chuenyam, T., Siangphoe, U., Ungsedhaphand, C., Phanuphak, P., Ruxrungtham, K. (2003). In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 32(5), 570-572.

2002

  • Pothikamjorn, S., Ruxrungtham, K., Thampanitchawong, P., Fuangthong, R., Srasuebkul, P., sangahsapaviriyah, A., Suttithavil, W., Klaewsongkram, J., Parisuthikul, V., Viravan, T., et al (2002). Impact of particulate air pollutants on allergic diseases, allergic skin reactivity and lung function. Asian Pacific Journal of Allergy and Immunology, 20(2), 77-83.
  • Cardiello, P., van Heeswijk, R., Hassink, E., Srasuebkul, P., Mahanontharit, A., Samor, T., Worarien, W., Beijnen, J., Hoetelmans, R., Ruxrungtham, K., et al (2002). Simplifying protease inhibitor therapy with Once-Daily Dosing of Saquinavir Soft-Gelatin Capsules/Ritonavir (1600/100mg): HIVNAT 001.3 Study. JAIDS-Journal of Acquired Immune Deficiency Syndromes, 29(5), 464-470.

2001

  • Srasuebkul, P. (2001). The Long-term efficacy of saquinavir-soft gelatin capsules plus either Combivir (AZT/3TC) or ddl/d4T in HIV1+ Thai patients pretreated with AZT/ddC: HIV-NAT 001.1 and 001.2. Royal College of Physicians of Thailand Meeting 2001, Thailand: Royal College of Physicians of Thailand.

For support on your academic profile contact .